- Home
- TVRD vs EDIT Comparison
TVRD vs EDIT Comparison
Compare TVRD & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVRD
- EDIT
- Stock Information
- Founded
- TVRD 2017
- EDIT 2013
- Country
- TVRD United States
- EDIT United States
- Employees
- TVRD N/A
- EDIT N/A
- Industry
- TVRD Biotechnology: Pharmaceutical Preparations
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TVRD Health Care
- EDIT Health Care
- Exchange
- TVRD Nasdaq
- EDIT Nasdaq
- Market Cap
- TVRD 246.5M
- EDIT 269.8M
- IPO Year
- TVRD N/A
- EDIT 2016
- Fundamental
- Price
- TVRD $40.68
- EDIT $3.95
- Analyst Decision
- TVRD Strong Buy
- EDIT Buy
- Analyst Count
- TVRD 5
- EDIT 11
- Target Price
- TVRD $59.20
- EDIT $4.56
- AVG Volume (30 Days)
- TVRD 67.6K
- EDIT 2.8M
- Earning Date
- TVRD 11-21-2025
- EDIT 11-03-2025
- Dividend Yield
- TVRD N/A
- EDIT N/A
- EPS Growth
- TVRD N/A
- EDIT N/A
- EPS
- TVRD N/A
- EDIT N/A
- Revenue
- TVRD N/A
- EDIT $38,901,000.00
- Revenue This Year
- TVRD N/A
- EDIT N/A
- Revenue Next Year
- TVRD N/A
- EDIT N/A
- P/E Ratio
- TVRD N/A
- EDIT N/A
- Revenue Growth
- TVRD N/A
- EDIT N/A
- 52 Week Low
- TVRD $8.13
- EDIT $0.91
- 52 Week High
- TVRD $42.10
- EDIT $4.07
- Technical
- Relative Strength Index (RSI)
- TVRD 70.68
- EDIT 71.08
- Support Level
- TVRD $36.05
- EDIT $3.01
- Resistance Level
- TVRD $42.10
- EDIT $4.06
- Average True Range (ATR)
- TVRD 2.87
- EDIT 0.30
- MACD
- TVRD 0.07
- EDIT 0.08
- Stochastic Oscillator
- TVRD 82.26
- EDIT 89.89
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.